PharmaShots | Incisive News in 3 Shots

Subscribe Now

AD

Eli Lilly Reports Results of Olumiant (baricitinib) in P-III BREEZE-AD1 and BREEZE-AD2 study for Moderate-to-Severe Atopic Dermatitis (AD)

Eli Lilly Reports Results of Olumiant (baricitinib) in P-III BREEZE-AD1 and BREEZE-AD2 study for Moderate-to-Severe Atopic Dermati...

February 5, 2019

Roche Discontinues P-III CREAD-1 and 2 Trials of Crenezumab in Patients with Early Alzheimer's Disease (AD)

Roche Discontinues P-III CREAD-1 and 2 Trials of Crenezumab in Patients with Early Alzheimer's Disease (AD)

January 31, 2019

Eli Lilly's Olumiant (baricitinib) Receives FDA's Fast Track Designation for Systemic Lupus Erythematosus (SLE)

Eli Lilly's Olumiant (baricitinib) Receives FDA's Fast Track Designation for Systemic Lupus Erythematosus (SLE)

December 14, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us